Noribogaine

Noribogaine
Clinical data
Other names	12-Hydroxyibogamine; Ibogamin-12-ol; O-Desmethylibogaine; O-Demethylibogaine; O-Noribogaine; (–)-Noribogaine
Routes of; administration	Oral
Legal status
Legal status	AU: S4 (Prescription only); US: Unscheduled (but still a Schedule I analogue due to being a main metabolite of C-I ibogaine);
Pharmacokinetic data
Elimination half-life	24–50 hours
Identifiers
	IUPAC name (1R,15R,17S,18S)-17-ethyl-3,13-diazapentacyclo[13.3.1.02,10.04,9.013,18]nonadeca-2(10),4(9),5,7-tetraen-7-ol;
CAS Number	481-88-9 ;
PubChem CID	3083548;
ChemSpider	2340735 ;
UNII	87T5QTN9SK;
ChEBI	CHEBI:146264;
ChEMBL	ChEMBL343956;
CompTox Dashboard (EPA)	DTXSID90963998 ;
Chemical and physical data
Formula	C19H24N2O
Molar mass	296.414 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CC[C@H]1C[C@@H]2C[C@@H]3[C@H]1N(C2)CCC4=C3NC5=C4C=C(C=C5)O;
	InChI InChI=1S/C19H24N2O/c1-2-12-7-11-8-16-18-14(5-6-21(10-11)19(12)16)15-9-13(22)3-4-17(15)20-18/h3-4,9,11-12,16,19-20,22H,2,5-8,10H2,1H3/t11-,12+,16+,19+/m1/s1 ; Key:RAUCDOKTMDOIPF-RYRUWHOVSA-N ;
	(verify)

Noribogaine, also known as O-desmethylibogaine or 12-hydroxyibogamine, is the principal psychoactive metabolite of the oneirogen ibogaine. It is thought to be involved in the antiaddictive effects of ibogaine-containing plant extracts, such as Tabernanthe iboga.

The drug appears to have a complex mechanism of action, with many different observed activities. Some of its most potent actions is atypical κ-opioid receptor agonism and serotonin reuptake inhibition. Noribogaine has potent psychoplastogenic effects similarly to ibogaine.

Noribogaine was first described in the scientific literature by at least 1958 and was first identified as a metabolite of ibogaine by 1995. It was first studied in humans in 2015.